inotersen
for Transthyretin Amyloid Cardiomyopathy
Inotersen is an RNA-targeting treatment for polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. It is self-administered as a weekly subcutaneous injection. hATTR is caused by a genetic mutation in the TTR gene, leading to amyloid fibril buildup that damages tissues, organs, and nerves. Tegsedi is an antisense oligonucleotide that blocks the production of TTR, reducing protein deposits and alleviating symptoms.
